查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126374

肝癌診斷市場－策略分析與預測（2026-2035）

Liver Cancer Diagnostics Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計肝癌診斷市場將從 2026 年的 51.1 億美元成長到 2035 年的 118.5 億美元，複合年成長率為 9.8%。

肝癌診斷市場正經歷重大變革，其驅動力在於早期檢測、精準腫瘤學和非侵入性診斷技術的模式轉移。該市場發展的一個關鍵特徵是，人們日益認知到及時準確的診斷對於提高生存率至關重要，因為肝癌通常在晚期才被確診，此時治療選擇有限。先進影像技術、分子診斷技術、液態生物檢體技術和人工智慧的整合，使得肝癌的檢測和發病機制研究能夠更快、更靈敏、更方便地進行。慢性B型和C型肝炎、非酒精性脂肪性肝病、肝硬化和代謝紊亂導致肝細胞癌在全球範圍內負擔日益加重，促使全球醫療保健系統擴大高危險群篩檢計畫。對多生物標記檢測、次世代定序和伴隨診斷的大量投資，正在鞏固肝癌診斷作為胃腸腫瘤學和精準醫學關鍵組成部分的地位。

市場促進因素

  • 肝細胞癌和慢性肝病盛行率的不斷上升是肝癌診斷市場的主要驅動力。日益加重的疾病負擔導致篩檢、監測、早期發現、診斷、治療選擇和疾病監測等應用領域對診斷檢測的需求持續成長。醫療系統正在擴展其診斷能力，以支持早期發現和個人化治療策略。這種需求推動了對各種診斷產品的需求，並促進了肝癌診斷的持續發展。全球乙型和丙型肝炎感染病例的增加，透過擴大監測和診斷檢測，進一步加速了市場成長。慢性病毒性肝炎仍是肝細胞癌的主要危險因素，因此對感染族群的肝癌篩檢需求持續成長。醫療機構正在擴大針對高風險患者的監測項目，以實現早期發現。診斷設備製造商正在開發專門的檢測解決方案，以支援與肝炎相關的肝癌篩檢。精準腫瘤學和伴隨診斷的日益普及推動了對分子譜分析和基因組檢測的需求。精準醫療需要準確的分子特徵分析來確定治療策略，從而持續推動了對先進診斷技術的需求。醫療機構正在拓展分子檢測能力，以支持個人化治療策略。診斷設備製造商正在開發專門的分子和基因組檢測解決方案，以支持精準腫瘤學的應用。癌症篩檢和監測計畫的擴展推動了對早期檢測技術的需求。醫療系統正在實施針對高風險族群的監測項目，以實現早期診斷並改善治療效果。這導致對高靈敏度影像學和生物標記檢測的持續需求。

市場限制因素

  • 先進分子診斷檢測的高成本限制了其在資源匱乏的醫療系統中的應用。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。低收入地區專業診斷資源的匱乏限制了病患獲得醫療服務和接受檢測的機會。專業檢查室和訓練有素的人員短缺限制了分子診斷的擴充性。嚴格的法規核准要求增加了製造商的研發時間和成本。對新診斷產品嚴格的證據要求構成了市場准入障礙。生物標記靈敏度和特異性的差異降低了臨床可靠性和應用率。新興診斷技術的保險報銷有限限制了患者獲得和接受這些技術的機會。

對技術和模式的洞察

  • 技術發展趨勢的特徵是分子診斷、液態生物檢體和人工智慧成像平台的重要性日益凸顯。影像診斷仍然佔據市場主導地位，超音波、CT 和 MRI 仍然是檢測和分期肝臟病變的主要工具。檢查室診斷和組織病理學在確診中繼續發揮著至關重要的作用。由於基因組分析、液態生物檢體和精準腫瘤學的日益普及，分子診斷正經歷最快的成長。細分市場分析表明，免疫組織化學仍然廣泛用於腫瘤表徵和病理評估。基於 PCR 的檢測方法繼續支持生物標記檢測和病毒診斷。次世代定序(NGS) 是成長最快的技術，這主要得益於其在精準腫瘤學和標靶治療選擇中日益廣泛的應用。 FISH 和免疫檢測繼續支持專門的生物標記評估和伴隨後續觀察應用。 AFP 仍然是肝癌篩檢和追蹤中最廣泛使用的生物標記。 AFP-L3 和 DCP/PIVKA-II 的應用正在不斷擴展，以提高診斷的敏感性和特異性。 Glypican-3 和新興的多生物標記組合在臨床上的重要性日益凸顯。由於早期發現對高風險族群至關重要，篩檢和監測成為關鍵應用。醫院是主要的終端使用者群體，診斷檢查室和癌症研究中心也不斷擴展其檢測能力。隨著人工智慧影像診斷技術的進步，病灶的檢測和表徵能力不斷提高，人工智慧的整合也變得愈發重要。

競爭格局與策略展望

  • 在競爭激烈的市場環境中，除了成熟的診斷和生命科學公司外，還有專注於分子診斷、影像和精準腫瘤學的供應商。羅氏開發全面的肝癌診斷解決方案，包括支持分子診斷、組織學診斷、伴隨診斷和精準腫瘤學的免疫組化平台。雅培提供免疫檢測、臨床化學平台、分子診斷和生物標記檢測解決方案，以支持肝病和腫瘤的診斷。西門子醫療提供先進的影像系統、臨床實驗室、免疫檢測和數位醫療技術，以支持肝癌的診斷。賽默飛世爾科技開發分子診斷分析、PCR技術、定序解決方案和精準腫瘤學產品，以支持肝癌的診斷。丹納赫提供分子診斷、基因組學技術、生命科學解決方案和檢查室自動化解決方案，以支援腫瘤生物標記檢測。安捷倫專注於病理解決方案、免疫組化分析、伴隨診斷和基因組學技術，以支持肝癌的診斷。 QIAGEN致力於開發分子診斷檢測、樣本製備技術、PCR試劑盒和伴隨診斷產品，以支持精準腫瘤學的發展。 Illumina是NGS平台領域的全球領導者，其平台可實現基因組分析、生物標記發現和精準腫瘤學應用。兩家公司都在透過液態生物檢體、多生物標記檢測和人工智慧平台方面的創新來拓展產品系列。在伴隨診斷開發和精準腫瘤學解決方案的需求推動下，診斷設備製造商、製藥公司和研究機構之間的策略合作日益增加。近期的一些重要進展包括：Guardant Health擴展了其液態生物檢體產品組合，新增了先進的多癌種基因組檢測功能；羅氏宣布推出增強型伴隨診斷解決方案，以支持肝癌的精準腫瘤學；Illumina擴展了其腫瘤定序應用，用於全面的腫瘤基因組分析；賽默飛世爾科技推出了用於固體癌診斷的更新版NGS工作流程。以及安捷倫科技公司擴展其免疫組織化學檢測產品，以支持肝癌的病理診斷。

簡明結論

  • 肝癌診斷市場預計將持續成長，這主要得益於疾病負擔、技術創新以及精準醫療的融合。從傳統診斷方法向非侵入性、基於分子技術的整合策略的轉變，標誌著胃腸腫瘤學領域的根本性變革。儘管高成本、有限的醫療服務取得途徑以及監管要求等挑戰依然存在，但對技術、夥伴關係和臨床檢驗的策略性投資正在為市場領導創造持續的競爭優勢。長期市場前景依然樂觀，肝癌診斷正發展成為精準腫瘤學的重要組成部分，為全球醫療體系的早期發現、治療選擇以及患者預後改善提供支持。

本報告的主要益處：

  • 深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
  • 競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策，以開發新的收入來源。
  • 適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

    產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

  • 歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
  • 競爭對手定位、策略和市場佔有率分析
  • 營收成長率及預測分析：依業務板塊及地區（國家）分類
  • 企業概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

  • 市場概述
  • 主要分析結果
  • 分析師意見
  • 策略建議

第2章 分析方法

  • 分析設計
  • 資料收集和分析方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章：全球肝癌診斷市場：概述、市場規模與預測

  • 市場定義和範圍
  • 行業概覽
  • 疾病演變與診斷趨勢
  • 主要市場趨勢
  • 實際成果值市場規模分析
  • 市場預測
  • 疾病盛行率分析
  • 已確診患者族群的分析
  • 肝癌診斷檢測次數的分析
  • 患者診斷路徑分析

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 新興技術
  • 產品創新
  • 肝癌液態生物檢體
  • 人工智慧在肝癌診斷的應用
  • 伴隨診斷的開發
  • 生物標記的發現
  • 技術藍圖

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章 全球肝癌診斷市場：展望分析

  • 分析：按診斷方式
    • 診斷影像
    • 臨床試驗
    • 組織病理學
    • 分子診斷
  • 分析：按技術
    • 免疫組織化學（IHC）
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 螢光原位雜合反應（FISH）
    • 免疫測量
  • 分析：透過生物標記
    • 胎兒球蛋白（AFP）
    • AFP-L3
    • 去羧基凝血酶原（DCP/PIVKA-II）
    • 醣蛋白聚醣-3 (GPC3)
    • 其他生物標記
  • 分析：透過臨床應用
    • 篩檢和監測
    • 早期檢測
    • 診斷
    • 治療方案
    • 疾病監測

第9章 全球肝癌診斷市場：細分市場分析

  • 依產品
    • 裝置
    • 試劑和耗材
    • 軟體
  • 透過技術
    • 免疫組織化學（IHC）
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 螢光原位雜合反應（FISH）
    • 免疫測量
    • 其他技術
  • 最終用戶
    • 醫院
    • 診斷檢查室
    • 學術研究機構
    • 癌症研究中心

第10章 全球肝癌診斷市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章 全球肝癌診斷市場：國別分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本
  • 中國
  • 韓國
  • 印度
  • 澳洲
  • 巴西
  • 墨西哥
  • 沙烏地阿拉伯
  • 南非

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 企業合併、商業夥伴關係和合作
  • 新產品發布

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • QIAGEN NV
  • bioMerieux
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Guardant Health, Inc.
  • Exact Sciences Corporation
  • Sysmex Corporation
  • Fujifilm Holdings Corporation
  • Leica Biosystems

第14章 全球肝癌診斷市場：商業預測分析

第15章 投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009086

The Liver Cancer Diagnostics Market is set to reach USD 11.85 billion in 2035, growing at a CAGR of 9.8 % from USD 5.11 billion in 2026.

The liver cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward early detection, precision oncology, and non-invasive diagnostic technologies. The market's evolution is characterized by the growing recognition that timely and accurate diagnosis is essential for improving survival outcomes, as liver cancer is frequently diagnosed at advanced stages when therapeutic options are limited. The convergence of advanced imaging modalities, molecular diagnostics, liquid biopsy technologies, and artificial intelligence is enabling faster, more sensitive, and increasingly accessible liver cancer detection and characterization. Healthcare systems worldwide are expanding surveillance programs among high-risk populations as the global burden of hepatocellular carcinoma continues to rise due to chronic hepatitis B and C infections, non-alcoholic fatty liver disease, cirrhosis, and metabolic disorders. The market is witnessing significant investment in multi-biomarker panels, next-generation sequencing, and companion diagnostics, positioning liver cancer diagnostics as a critical component of gastrointestinal oncology and precision medicine.

Market Drivers

  • The increasing prevalence of hepatocellular carcinoma and chronic liver diseases represents the primary driver for the liver cancer diagnostics market. Rising disease burden creates sustained demand for diagnostic testing across screening, surveillance, early detection, diagnosis, treatment selection, and disease monitoring applications. Healthcare systems are expanding diagnostic capacity to support early detection and personalized treatment strategies. This requirement strengthens demand for diagnostic products across all modalities, resulting in sustained growth in liver cancer diagnostic utilization. Rising hepatitis B and hepatitis C infections globally are further accelerating market growth through increased surveillance and diagnostic testing. Chronic viral hepatitis remains a major risk factor for hepatocellular carcinoma, creating sustained demand for liver cancer screening among infected populations. Healthcare providers are expanding surveillance programs for high-risk patients to enable earlier detection. Diagnostic manufacturers are developing specialized testing solutions to support hepatitis-related liver cancer screening. The growing adoption of precision oncology and companion diagnostics is driving demand for molecular profiling and genomic testing. Precision medicine requires accurate molecular characterization to guide therapeutic decisions, creating sustained demand for advanced diagnostic technologies. Healthcare providers are expanding molecular testing capabilities to support personalized treatment strategies. Diagnostic manufacturers are developing specialized molecular and genomic testing solutions to support precision oncology applications. The expansion of cancer screening and surveillance programs is increasing demand for early detection technologies. Healthcare systems are implementing surveillance programs for high-risk populations to enable earlier diagnosis and improve outcomes. This creates sustained demand for sensitive imaging modalities and biomarker testing.

Market Restraints

  • High costs associated with advanced molecular diagnostic testing limit adoption in resource-constrained healthcare systems. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited access to specialized diagnostics in low-income regions restricts patient access and adoption. The shortage of specialized laboratories and trained personnel limits the scalability of molecular diagnostics. Stringent regulatory approval requirements increase development timelines and costs for manufacturers. The rigorous evidence requirements for new diagnostic products create barriers to market entry. Variability in biomarker sensitivity and specificity reduces clinical confidence and adoption. Reimbursement limitations for emerging diagnostic technologies restrict patient access and adoption.

Technology and Modality Insights

  • The technology landscape is characterized by the growing importance of molecular diagnostics, liquid biopsy, and AI-enabled imaging platforms. Imaging diagnostics continue to dominate the market as ultrasound, CT, and MRI remain the primary tools for liver lesion detection and disease staging. Laboratory diagnostics and histopathology remain essential for diagnosis confirmation. Molecular diagnostics are experiencing the fastest growth due to increasing adoption of genomic profiling, liquid biopsy, and precision oncology. The segment analysis reveals that immunohistochemistry remains widely utilized for tumor characterization and pathology evaluation. PCR-based testing continues supporting biomarker detection and viral diagnostics. NGS is the fastest-growing technology owing to increasing use in precision oncology and targeted therapy selection. FISH and immunoassays continue supporting specialized biomarker evaluation and companion diagnostic applications. AFP remains the most widely utilized biomarker for liver cancer screening and monitoring. AFP-L3 and DCP/PIVKA-II are increasingly adopted to improve diagnostic sensitivity and specificity. Glypican-3 and emerging multi-biomarker panels continue gaining clinical importance. Screening and surveillance represent critical applications because of the importance of early detection in high-risk populations. Hospitals represent the leading end-user segment, with diagnostic laboratories and cancer research centers expanding testing capabilities. The integration of AI is becoming increasingly important as AI-assisted imaging improves lesion detection and characterization.

Competitive and Strategic Outlook

  • The competitive landscape features established diagnostics and life science companies alongside specialized molecular, imaging, and precision oncology providers. Roche develops comprehensive liver cancer diagnostic solutions including molecular diagnostics, tissue diagnostics, companion diagnostics, and immunohistochemistry platforms supporting precision oncology. Abbott provides immunoassays, clinical chemistry platforms, molecular diagnostics, and biomarker testing solutions supporting liver disease and oncology diagnostics. Siemens Healthineers offers advanced imaging systems, laboratory diagnostics, immunoassays, and digital healthcare technologies supporting liver cancer diagnosis. Thermo Fisher Scientific develops molecular diagnostic assays, PCR technologies, sequencing solutions, and precision oncology products supporting liver cancer diagnostics. Danaher provides molecular diagnostics, genomics technologies, life science solutions, and laboratory automation supporting oncology biomarker testing. Agilent specializes in pathology solutions, immunohistochemistry assays, companion diagnostics, and genomic technologies supporting liver cancer diagnosis. QIAGEN develops molecular diagnostic assays, sample preparation technologies, PCR kits, and companion diagnostics supporting precision oncology. Illumina is a global leader in NGS platforms enabling genomic profiling, biomarker discovery, and precision oncology applications. Companies are pursuing product portfolio expansion through innovation in liquid biopsy, multi-biomarker panels, and AI-enabled platforms. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Guardant Health expanding its liquid biopsy portfolio with advanced multi-cancer genomic testing capabilities. Roche introduced enhanced companion diagnostic solutions supporting precision oncology for liver cancer. Illumina expanded oncology sequencing applications for comprehensive tumor genomic profiling. Thermo Fisher Scientific launched updated NGS workflows for solid tumor diagnostics. Agilent Technologies expanded immunohistochemistry assay offerings supporting liver cancer pathology.

Short Conclusion

  • The liver cancer diagnostics market is positioned for sustained growth driven by the convergence of disease burden, technological innovation, and precision medicine. The transition from conventional diagnostic approaches toward integrated non-invasive and molecular strategies represents a fundamental shift in gastrointestinal oncology. While challenges related to high costs, access limitations, and regulatory requirements persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with liver cancer diagnostics evolving into a critical component of precision oncology, supporting early detection, treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Global Liver Cancer Diagnostics Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Disease Overview
  • 3.3 Disease Evolution and Diagnostic Landscape
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast (2026-2035)
  • 3.7 Disease Prevalence Analysis
  • 3.8 Diagnosed Patient Population Analysis
  • 3.9 Liver Cancer Diagnostic Testing Volume Analysis
  • 3.10 Patient Diagnostic Pathway Analysis

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Technologies
  • 6.2 Product Innovation
  • 6.3 Liquid Biopsy for Liver Cancer
  • 6.4 Artificial Intelligence in Liver Cancer Diagnostics
  • 6.5 Companion Diagnostics Development
  • 6.6 Biomarker Discovery
  • 6.7 Technology Roadmap

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Global Liver Cancer Diagnostics Market Landscape Analysis

  • 8.1 Analysis by Diagnostic Modality
    • 8.1.1 Imaging Diagnostics
    • 8.1.2 Laboratory Diagnostics
    • 8.1.3 Histopathology
    • 8.1.4 Molecular Diagnostics
  • 8.2 Analysis by Technology
    • 8.2.1 Immunohistochemistry (IHC)
    • 8.2.2 Polymerase Chain Reaction (PCR)
    • 8.2.3 Next-Generation Sequencing (NGS)
    • 8.2.4 Fluorescence In Situ Hybridization (FISH)
    • 8.2.5 Immunoassays
  • 8.3 Analysis by Biomarker
    • 8.3.1 Alpha-Fetoprotein (AFP)
    • 8.3.2 AFP-L3
    • 8.3.3 Des-Gamma-Carboxy Prothrombin (DCP/PIVKA-II)
    • 8.3.4 Glypican-3 (GPC3)
    • 8.3.5 Other Biomarkers
  • 8.4 Analysis by Clinical Application
    • 8.4.1 Screening & Surveillance
    • 8.4.2 Early Detection
    • 8.4.3 Diagnosis
    • 8.4.4 Treatment Selection
    • 8.4.5 Disease Monitoring

9. Global Liver Cancer Diagnostics Market Segment Analysis (2021-2035)

  • 9.1 By Product
    • 9.1.1 Instruments
    • 9.1.2 Reagents & Consumables
    • 9.1.3 Software
  • 9.2 By Technology
    • 9.2.1 Immunohistochemistry (IHC)
    • 9.2.2 Polymerase Chain Reaction (PCR)
    • 9.2.3 Next-Generation Sequencing (NGS)
    • 9.2.4 Fluorescence In Situ Hybridization (FISH)
    • 9.2.5 Immunoassays
    • 9.2.6 Other Technologies
  • 9.3 By End User
    • 9.3.1 Hospitals
    • 9.3.2 Diagnostic Laboratories
    • 9.3.3 Academic & Research Institutes
    • 9.3.4 Cancer Research Centers

10. Global Liver Cancer Diagnostics Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Global Liver Cancer Diagnostics Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 Spain
  • 11.8 Japan
  • 11.9 China
  • 11.10 South Korea
  • 11.11 India
  • 11.12 Australia
  • 11.13 Brazil
  • 11.14 Mexico
  • 11.15 Saudi Arabia
  • 11.16 South Africa

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd.
    • 13.1.1 Company Overview
    • 13.1.2 Financials
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Developments
  • 13.2 Abbott Laboratories
    • 13.2.1 Company Overview
    • 13.2.2 Financials
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Developments
  • 13.3 Siemens Healthineers AG
    • 13.3.1 Company Overview
    • 13.3.2 Financials
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Developments
  • 13.4 Thermo Fisher Scientific Inc.
    • 13.4.1 Company Overview
    • 13.4.2 Financials
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Developments
  • 13.5 Danaher Corporation
    • 13.5.1 Company Overview
    • 13.5.2 Financials
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Developments
  • 13.6 Agilent Technologies, Inc.
    • 13.6.1 Company Overview
    • 13.6.2 Financials
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Developments
  • 13.7 QIAGEN N.V.
    • 13.7.1 Company Overview
    • 13.7.2 Financials
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Developments
  • 13.8 bioMerieux
    • 13.8.1 Company Overview
    • 13.8.2 Financials
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Developments
  • 13.9 Bio-Rad Laboratories, Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Financials
    • 13.9.3 Product Portfolio
    • 13.9.4 Recent Developments
  • 13.10 Illumina, Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Financials
    • 13.10.3 Product Portfolio
    • 13.10.4 Recent Developments
  • 13.11 Guardant Health, Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Financials
    • 13.11.3 Product Portfolio
    • 13.11.4 Recent Developments
  • 13.12 Exact Sciences Corporation
    • 13.12.1 Company Overview
    • 13.12.2 Financials
    • 13.12.3 Product Portfolio
    • 13.12.4 Recent Developments
  • 13.13 Sysmex Corporation
    • 13.13.1 Company Overview
    • 13.13.2 Financials
    • 13.13.3 Product Portfolio
    • 13.13.4 Recent Developments
  • 13.14 Fujifilm Holdings Corporation
    • 13.14.1 Company Overview
    • 13.14.2 Financials
    • 13.14.3 Product Portfolio
    • 13.14.4 Recent Developments
  • 13.15 Leica Biosystems
    • 13.15.1 Company Overview
    • 13.15.2 Financials
    • 13.15.3 Product Portfolio
    • 13.15.4 Recent Developments

14. Global Liver Cancer Diagnostics Market Commercial Forecast Analysis

  • 14.1 Imaging Diagnostics
  • 14.2 Immunohistochemistry (IHC)-Based Diagnostics
  • 14.3 Molecular Diagnostic Tests
  • 14.4 Alpha-Fetoprotein (AFP) Tests
  • 14.5 Liquid Biopsy Tests
  • 14.6 Next-Generation Sequencing (NGS)-Based Tests
  • 14.7 Companion Diagnostic Tests

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends